As comparable mutations of the FAS gene have previously been designated by us and others as subtype-specific recurrent alterations in PCMZL [19,20], we finally favored to classify these two ambiguous cases as PCMZL rather than PCFBCL based on these molecular findings. The gene discussed is FAS; the disease is primary cutaneous marginal zone B-cell lymphoma.